Promoter hypermethylation of the cysteine protease RECK may cause metastasis of osteosarcoma

Tumor Biology

Volumn 36, Issue 12, 2015, Pages 9511-9516

  Wang, Leisheng ^a,b   Ge, Junbo ^b   Ma, Tian ^c   Zheng, Yanpin ^a   Lv, Shiqiao ^b   Li, Yu ^b   Liu, Shaoxian ^b  

^a SHANDONG UNIVERSITY   (China)

^b YANTAISHAN HOSPITAL   (China)

^c Qixia City People s Hospital   (China)

Author keywords

Bone tumors; Metastasis; Osteosarcoma; Promoter hypermethylation; RECK

Indexed keywords

CYSTEINE PROTEINASE; FOCAL ADHESION KINASE; GELATINASE B; INTEGRIN; REVERSION INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIF; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MMP9 PROTEIN, HUMAN; RECK PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA METHYLATION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; AGED; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROMOTER REGION;

ADULT; AGED; BIOMARKERS, TUMOR; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM METASTASIS; OSTEOSARCOMA; PROGNOSIS; PROMOTER REGIONS, GENETIC;

EID: 84952877228     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3688-4     Document Type: Article

References (15)

1. Chang L, Asatrian G, Dry SM, James AW. Circulating tumor cells in sarcomas: a brief review. Med Oncol. 2015;32:430.
2. Kim SS, Park YK. Significance of MTA1 in the molecular characterization of osteosarcoma. Cancer Metastasis Rev. 2014;33:981–91.
3. Ren L, Khanna C. Role of ezrin in osteosarcoma metastasis. Adv Exp Med Biol. 2014;804:181–201.
4. Yang G, Yuan J, Li K. EMT transcription factors: implication in osteosarcoma. Med Oncol. 2013;30:697.
5. Li H, Zhang K, Liu LH, Ouyang Y, Bu J, Guo HB. A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma. Tumour Biol. 2014;35:5487–91.
6. Poudel B, Kim DK, Ki HH, Kwon YB, Lee YM, Kim DK. Downregulation of ERK signaling impairs U2OS osteosarcoma cell migration in collagen matrix by suppressing MMP9 production. Oncol Lett. 2014;7:215–8.
7. Sun D, Wang X, Zhang H, Deng L, Zhang Y. MMP9 mediates MICA shedding in human osteosarcomas. Cell Biol Int. 2011;35:569–74.
8. Clark JC, Akiyama T, Thomas DM, Labrinidis A, Evdokiou A, Galloway SJ, et al. RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model. Cancer. 2011;117:3517–28.
9. Xu J, Wu S, Shi X. Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma. J Orthop Res. 2010;28:1621–5.
10. Kang HG, Kim HS, Kim KJ, Oh JH, Lee MR, Seol SM, et al. RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness. J Orthop Res. 2007;25:696–702.
11. Zhang C, Ling Y, Zhang C, Xu Y, Gao L, Li R, et al. The silencing of RECK gene is associated with promoter hypermethylation and poor survival in hepatocellular carcinoma. Int J Biol Sci. 2012;8:451–8.
12. Lu XX, Zhang SM, Fang Y, Wang ZT, Xie JJ, Zhan Q, et al. Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma. Tumour Biol. 2013;34:3339–43.
13. Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 2013;25:398–406.
14. Noda M, Rodan GA. Type beta transforming growth factor regulates expression of genes encoding bone matrix proteins. Connect Tissue Res. 1989;21:71–5.
15. Baptista AM, Camargo AF, Filippi RZ, Oliveira CR, Azevedo Neto RS, Camargo OP. Correlation between the expression of VEGF and survival in osteosarcoma. Acta Ortop Bras. 2014;22:250–5.